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Abstract
Protein catabolism should be reduced and protein synthesis promoted
with parenteral nutrion (PN). Amino acid (AA) solutions should always
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H. J. Boehles2be infused with PN. Standard AA solutions are generally used, whereas
I. Blumenstein1specially adapted AA solutions may be required in certain conditions
C. Goeters3such as severe disorders of AA utilisation or in inborn errors of AA
metabolism. An AA intake of 0.8 g/kg/day is generally recommended R. Schulz4
for adult patients with a normal metabolism, which may be increased
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to 1.2–1.5 g/kg/day, or to 2.0 or 2.5 g/kg/day in exceptional cases.
Sufficient non-nitrogen energy sources should be added in order to as-
sure adequate utilisation of AA. A nitrogen calorie ratio of 1:130 to guidelines for
1:170 (g N/kcal) or 1:21 to 1:27 (g AA/kcal) is recommended under parenteral nutrition of
normal metabolic conditions. In critically ill patients glutamine should The Germanbe administered parenterally if indicated in the form of peptides, for
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example 0.3–0.4 g glutamine dipeptide/kg body weight/day (=0.2–0.26
g glutamine/kg body weight/day). No recommendation can be made
for glutamine supplementation in PN for patients with acute pancreatitis
or after bone marrow transplantation (BMT), and in newborns. The ap- 1 Dept. Internal Medicine,
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plication of arginine is currently not warranted as a supplement in PN
in adults. N-acetyl AA are only of limited use as alternative AA sources.
There is currently no indication for use of AA solutions with an increased
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content of glycine, branched-chain AAs (BCAA) and ornithine-α-ketoglut-
arate (OKG) in all patients receiving PN. AA solutions with an increased
proportion of BCAA are recommended in the treatment of hepatic en-
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Ein Proteinkatabolismus soll bei parenteraler Ernährung (PE) vermindert
und anabole Stoffwechselprozesse gefördert werden. Standard-Amino-
säure (AS)-Lösungenwerden empfohlen, falls nicht in Sondersituationen
z. B. bei schweren AS-Verwertungsstörungen oder bei angeborenen
Stoffwechselstörungen spezifisch adaptierte AS-Lösungen eingesetzt
werden müssen. Für erwachsene Patienten in ausgeglichenem Stoff-
wechselzustand wird eine AS-Zufuhr von 0,8 g/kg/Tag empfohlen, die
auf 1,2–1,5 g/kg/Tag oder in Ausnahmefällen auch auf 2,0–2,5
g/kg/Tag gesteigert werden kann. Zur Gewährleistung einer angemes-
senen Utilisation von AS sollten ausreichend Nicht-Stickstoff-Energieträ-
ger zugegeben werden. Das angestrebte Verhältnis zwischen Stickstoff-
und Energiezufuhr (Stickstoff-Kalorien-Verhältnis) sollte unter Normal-
bedingungen 1:100–1:130 (g N:kcal) bzw. 1:16–1:21 (g AS:kcal) betra-
gen. Glutamin sollte parenteral bei kritisch Kranken, sofern indiziert, in
Form von Peptiden verabreicht werden, wie z.B. 0,3–0,4 g Glutamin-
Dipepetid/kg KG/Tag (entsprechend 0,2–0,26 g Glutamin/kg KG/Tag).
Für Patientenmit akuter Pankreatitis, nach Knochenmarkstransplanta-
tion sowie für Neugeborene kann derzeit keine Empfehlung für eine
Glutaminsupplementierung mit der PE ausgesprochen werden. Der
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Einsatz von Arginin als Supplement in der PE beim Erwachsenen ist
derzeit nicht gerechtfertigt. Den N-azetylierten AS kommen als alterna-
tive Aminosäurenquellen zur Zeit nur eine begrenzte Bedeutung zu. Für
eine generelle Verwendung von AS-Lösungenmit einemerhöhten Gehalt
von Glyzin und verzweigtkettigten AS (VKAS) wie auch für Ornithin-α-
Ketoglutarat (OKG) besteht keine gesicherte Indikation. DieWirksamkeit
von AS-Lösungen mit erhöhtem Anteil an VKAS in der Behandlung der
hepatischen Enzephalopathie (III–IV) wird empfohlen.




An important objective of parenteral nutrition (PN), in
addition to meeting energy requirements, is to maintain
vital organ structure and function. Protein catabolism
should be decreased and protein synthesis promoted.
Amino acids (AA), the building blocks in protein synthesis,
are classified as dispensable, indispensable, and condi-
tionally dispensable AA and their precursors (Table 1).
Recommended AA supplies with PN are generally based
on oral/enteral intake recommendations (Table 2), but
data from animal studies [1], [2], [3] and clinical trials




• AA should always be infused with PN (A).
• Contraindications to the infusion of standard AA solu-
tions are inborn errors of AA metabolism (e.g.
phenylketonuria,maple syrup urine disease, cystinuria)
as well as severe disorders of AA utilisation (e.g. severe
liver dysfunction). Specially adapted AA solutions
should be used when necessary (A).
Commentary
AA solutions are an essential part of complete PN for the
maintenance of nitrogen homeostasis [5].
Contraindications to the infusion of standard AA solutions
are inborn errors of AA metabolism (cf. chapter
“Neonatology/Paediatrics” http://www.egms.de/en/gms/
2009-7/000074.shtml) as well as severe disorders of
AA utilisation such as severe liver dysfunction (cf. chapters
“Gastroenterology” http://www.egms.de/en/gms/2009-
7/000072.shtml and “Hepatology” http://www.egms.de/
en/gms/2009-7/000071.shtml) or renal disorders (cf.
chapter “Parenteral nutrition in patients with renal failure”
http://www.egms.de/en/gms/2009-7/000070.shtml).




• None of the presently available AA solutions meet all
the physiological requirements of dispensable and in-
dispensable AA.
Commentary
Crystalline AA solutions used presently in PN contain
between 3.5 and 15% of weight as AAs (osmolarity 450
to 1450 mosmol/l) (Table 3 and Table 4). None of the
currently available solutions provide ideal quantities of
indispensable and dispensable AA [6] because of either
poor solubility of individual AA (tyrosine, cysteine) or in-
stability in aqueous solutions (e.g. glutamine dissociates
into pyroglutamate and ammoniac). Dipeptide solutions,
which have recently become available, allow for an im-
provement in the intravenous administration of larger




• An AA intake of 0.8 g/kg/day is recommended for an
adult patient on total PN with a normal metabolism
and normal organ functions, irrespective of age and
sex (B). Depending on metabolic requirements, this
can be increased to 1.2–1.5 g/kg/day (A), or to 2.0 or
2.5 g/kg/day (C) in exceptional cases.
• Sufficient non-nitrogen energy sources should be
added in order to guarantee optimumutilisation of AA.
A nitrogen calorie ratio between 1:130 and 1:170 (g
N/kcal) or 1:21 to 1:27 (g AA/kcal) is recommended
under normal metabolic conditions (A).
Commentary
A recently published meta-analysis of nitrogen balance
studies, investigating the protein requirements of healthy
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Table 1: Classification of amino acids in adults and school children
Table 2: Dietary reference values for enteral protein intake [55]
Table 3: Recommended intakes for indispensable amino acids (mg/kg body weight/day, [55])
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Table 4: Available parenteral amino acid solutions for adults (g/L) (Version 05/2004)
adults, has recommended an oral protein intake of 0.8
g/kg/day irrespective of age and sex [5].
As the objective of PN therapy in critically ill patients is
to minimise the loss lean body cell mass, the above-
mentioned protein requirement for healthy adults should
be adjusted according to the severity of the clinical pic-
ture. For example, in non-hypercatabolic patients with
acute kidney failure or during the polyuric recovery phase
after acute kidney failure, a protein intake of 1.0–1.3
g/kg /day is recommended to maintain nitrogen balance
[7]. An intake of 1.2–1.5 g/kg/day is recommended in
patients with severe acute pancreatitis [8]. The previously
suggested upper limit of 1.5 g/kg/day may be exceeded
in extremely catabolic, critically ill patients depending on
their energy requirements. An intake of up to 2.5 g/kg
body weight/day is recommended by some authors in
order to achieve a positive nitrogen balance, particularly
in burns patients with no kidney or liver insufficiency, as
well as in critically ill patients requiring dialysis due to
renal insufficiency [9], [10], [11]. An adjustment of the
protein intake to >1.5 g/kg body weight/day is also rec-
ommended in malnourished patients [12]. The level of
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intake should generally not exceed an amount allowing
for a serum urea value near the upper end of the refer-
ence range.
Sufficient non-nitrogen energy sources should be added
in order to guarantee the optimum utilisation of AAs [13].
A nitrogen calorie ratio between 1:130 and 1:170 (g
N/kcal) or 1:21 to 1:27 (g AA/kcal) is recommended
under normalmetabolic conditions (A). In contrast to data
on oral/enteral protein intake, there are no sufficient data
to determine the optimal ratio of indispensable/total AA
(E/T ratio) in PN.
Conditionally indispensable amino
acids
New studies are increasingly questioning the conventional
classification of indispensable and dispensable AA in
clinical nutrition. Numerous data point out that some of
the so-called dispensable AAs are conditionally indispens-
able in adults under certain medical situations [14], and
therefore, should be supplied [15].
Glutamine
In catabolic illnesses (e.g. elective surgery, trauma, pan-
creatitis, burns, high-dosage chemotherapy), massive
intracellular glutamine deficiency occurs inmuscles.Many
studies have highlighted the fact that in these illnesses
glutamine is released from muscle tissue and lungs and
is made available for other organs (e.g. intestines, kidney)
and immune cells. Thus, glutamine is themost important
AA for nitrogen transport between organs and organ sys-
tems.
• Critically ill patients receiving no enternal nutrition
(including burns and trauma patients) should receive
a sufficient amount of glutamine dipeptides (0.3–0.4
g glutamine dipeptide/kg body weight/day = 0.2–0.26
g glutamine/kg body weight/day) in PN (A).
• No recommendation can be made for glutamine sup-
plementation in patients with acute pancreatitis due
to the lack of data (C).
• No recommendation can be made for glutamine sup-
plementaion in PN for patients after bone marrow
transplantation (BMT), and in newborns, due to the
availability of limited and inconsistent data (C).
Commentary
Twelve prospective randomised studies and 2 meta-
analyses [16], [17] have established the efficacy of
glutamine-containing PN in both surgical [18], [19], [20],
[21], [22], [23], [24] and other critically ill patients [25],
[26], [27], [28]. Administration of glutamine resulted in
a dose-dependent reduction in infection-related compli-
cations as well as length of hospital stay in critically ill
patients who had undergone surgery. Likewise, inmedical
intensive care patients there was a significant reduction
in complications and mortality.
Although, two randomised studies have been published
[29], [30] on the effect of glutamine administration on
patients with acute pancreatitis, no recommendation can
be made due to the small number of patients included
in the study. In patients after bone marrow transplant-
ation, no consensus can be reached regarding the admin-
istration of glutamine [31], [32], [33].
• When indicated, glutamine should be administered
parenterally, in the form of peptides (A).
Commentary
Commercially available AA solutions contain only small
amounts of cysteine, tyrosine or glutamine due to their
low solubility or instability. These AAs are regarded as
semi-essential in certain situations. Recently, di- and
tripeptides of cysteine, glutamine and tyrosine have been
synthesised that are hydolysed rapidly to provide the re-
spective AA.
Glutamine-containing parenteral solutionsmust be freshly
prepared, under strict aseptic conditions at 4°C due to
their low solubility in aqueous solutions and their ten-
dency to be degraded to pyroglutamate, which involves
a release of ammonia. The concentration of glutamine in
the aqueous parenteral solution should not exceed
1–1.5% [w/v] in order to prevent precipitation. The
amount of glutamine that can be administered is there-
fore limited, as large amounts of fluid have to be infused
to overcome the low solubility of glutamine.
Arginine
• The application of arginine is not currently warranted
as a supplement in PN in adults (C).
Commentary
There are only a few isolated studies on the parenteral
use of arginine in patients. In critically ill patients, arginine
has a favourable effect on the function of immune cells
and on the progression of wound healing [34], [35]. Argin-
ine plays a key role in nitrogen homeostasis, in the
formation of creatine and the polyamines, and is themost
important substrate in the formation of nitric oxide (NO).
In burn patients, for example, a significant drop in serum
arginine concentration was observed due to an increased
synthesis of ornithine (starting substrate of polyamine
synthesis) [34], [35]. An increase in arginine intake from
5% to 7% of total AA may result in immunomodulatory
effects [34], [35], [36]. Routine parenteral supplementa-
tion of arginine is not recommended due to the insuffi-
cient data on safety and efficacy.
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N-acetyl amino acids
• N-acetyl AA are metabolised to a limited extent in
humans and are, therefore, only of limited use as al-
ternative AA sources in clinical nutrition at the present
time (B).
• N-acetyl cysteine is recommended to prevent contrast
agent (CA)-induced nephropathy (A).
Commentary
Initial studies on animals provided convincing data that
the soluble and stable N-acetyl AA, i.e. acetyl cysteine,
acetyl tyrosine and acetyl glutamine, are effectively
deacetylised in vivo and the released AA are well metab-
olised [37]. Subsequent studies on humans, however,
did not support this data. In humans, 50% of the sub-
strates are excreted unchanged in the urine. Compared
to dipeptides, the half-life of acetyl cysteine after intraven-
ous administration is approximately 40 times higher [38],
[39]. However, effectiveness of N-acetyl cysteine (600
mg intravenously 12 hours before and 12 hours after
administration of CA) in prevention of renal failure after
CA administration has been demonstrated in many
studies [40], [41].
Glycine, branched-chain amino acids,
ornithine-alpha-ketoglutarate
• There is currently no indication for use of AA solutions
with an increased content of glycine, branched-chain
AAs (BCAA) and ornithine-α-ketoglutarate (OKG) in all
patients receiving PN (I).
• AA solutions with an increased proportion of BCAA are
recommended in the treatment of hepatic encephalo-
pathy (III–IV) as they are effective in alleviating the
encephalopathy (A).
Commentary
The dispensable, soluble AA glycine is the only naturally
occurring AA which is neither chirally nor optically active.
It is an essential part of scleroproteins as well as an inter-
mediate in the biosynthesis of porphyrins, purines, creat-
inine and glutathione. Glycine serves as a flexible bond
for proteins, which is necessary for helix formation, and
acts as an extracellular signal protein. It is cytoprotective
in ischemic insults, hypoxia and reperfusion damage [42].
Orally administered glycine in conjunction with glutamine
serves to repair cells, the metabolic adaption, and pro-
tects intestinal mucosa after intestinal resection [43],
[44]. Administration of high dose glycine with glutamine
resulted in a good compatibility and uptake in patients
with polytrauma [45].
The use of parenteral AA solutions, which are concen-
trated with BCAA, is well-known. BCAA supplementation
is used in multiple conditions such as liver disorders
(especially hepatic encephalopathy), sepsis, trauma,
disorders of gastric motility, and the prevention of failure
of the respiratorymusculature during artificial respiration.
The effectiveness of BCAA in the treatment of hepatic
encephalopathy was tested in seven controlled studies,
where the individual results were contradictory, but in
meta-analysis showed an improvement in encephalo-
pathy. However, no benefit was observed in the survival
rate [46].
Until to date, there are only small randomised studies
that have investigated the use of AA solutions with an
increased proportion of BCAA, in critically ill patients and
demonstrated an improvement in clinical status [47],
[48], [49], [50], The small number of patients in these
studies does not justify a general recommendation.
OKG consists of one molecule of α-ketoglutarate (AKG)
and 2 molecules of ornithine. After intravenous adminis-
tration, it dissociates into the two parts in blood [51].
OKG is well tolerated and is associated with the stimu-
lated release of insulin and growth hormone, and it serves
as a substrate for polyamine synthesis. The components
of OKG participate in glutamine biosynthesis. In small
studies, intravenous administration of OKG in post-
operative and critically ill patients results in protein con-
servation, stimulation of protein synthesis in themuscles,
and reduction in degradation of the muscular glutamine
pool [52], [53], [54].
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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